21 January 2019 - In 2018, Green Shield Canada launched its pilot Biosimilar Transition Program, through 3 plan sponsors, under which patients already receiving biologics were switched to biosimilars. Now that the pilot is complete, the payer is calling the program a success.

In 2016, not-for-profit health benefits company Green Shield Canada (GSC) started to give biosimilars preferred product listings on its formularies, covering reference biologics only in exceptional circumstances for patients who were new to biologic therapy. 

Then, in 2018, GSC launched a pilot Biosimilar Transition Program, through 3 plan sponsors, under which patients already receiving biologics were switched to biosimilars. Now that the pilot is complete, the payer is calling the program a success.

Read Center for Biosimilars article